Review of microdialysis in brain tumors, from concept to application: First annual Carolyn Frye-Halloran symposium

Ramsis K. Benjamin, Fred H. Hochberg, Elizabeth Fox, Peter M. Bungay, William F Elmquist, Clinton F. Stewart, James M. Gallo, Jerry M. Collins, Robert P. Pelletier, John F. de Groot, Robert C. Hickner, Idil Cavus, Stuart A. Grossman, O. Michael Colvin

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


In individuals with brain tumors, pharmacodynamic and pharmacokinetic studies of therapeutic agents have historically used analyses of drug concentrations in serum or cerebrospinal fluid, which unfortunately do not necessarily reflect concentrations within the tumor and adjacent brain. This review article introduces to neurological and medical oncologists, as well as pharmacologists, the application of microdialysis in monitoring drug metabolism and delivery within the fluid of the interstitial space of brain tumor and its surroundings. Microdialysis samples soluble molecules from the extracellular fluid via a semipermeable membrane at the tip of a probe. In the past decade, it has been used predominantly in neurointensive care in the setting of brain trauma, vasospasm, epilepsy, and intracerebral hemorrhage. At the first Carolyn Frye-Halloran Symposium held at Massachusetts General Hospital in March 2002, the concept of microdialysis was extended to specifically address its possible use in treating brain tumor patients. In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials.

Original languageEnglish (US)
Pages (from-to)65-74
Number of pages10
Issue number1
StatePublished - Jan 2004


Dive into the research topics of 'Review of microdialysis in brain tumors, from concept to application: First annual Carolyn Frye-Halloran symposium'. Together they form a unique fingerprint.

Cite this